We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · May 16, 2018

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins



Additional Info

Disclosure statements are available on the authors' profiles:

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
Circulation 2018 May 07;[EPub Ahead of Print], KK Ray, RM Stoekenbroek, D Kallend, LA Leiter, U Landmesser, RS Wright, P Wijngaard, JJ Kastelein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading